IMPLEMENTATION LEVEL

IFI

AFFECTED FLOW

Inflow

ANNOUNCED AS TEMPORARY

No

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

firm-specific

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: 06 Aug 2020 | Removal date: open ended

State loan

On 6 August 2020, the European Investment Bank (EIB) signed a loan agreement with Danish drug developer Evaxion Biotech to the value of EUR 20 million (approx. USD 23.7 million). The loan will support the development of a platform for drug discovery exploiting Artificial Intelligence (AI) and the pipeline of potential vaccines and treatments targeting infectious diseases.

A state act in the GTA database is assessed solely in terms of the extent to which its implementation affects foreign commercial interests. On this metric, the investment support granted here is discriminatory.

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

AFFECTED SECTORS AND PRODUCTS

352 Pharmaceutical products
3002 Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micr
300210 Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes
300220 Vaccines for human medicine

Please report this page in case you detect an inaccuracy in its content.